CBIS is the worst offender because the number of fluff PRs it put out without follow through. Why don't you go through their old PRs and see if you can identify and assess their success rate?
What happened to that drug development program? and university? Show us the picture of the drug and, if it is not too much to ask, the revenue?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.